Results 11 to 20 of about 4,667 (238)
Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase. [PDF]
PLoS ONE, 2013 Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny ...
Hong Ma +5 more
doaj +5 more sources
Bruton’s Tyrosine Kinase and Its Isoforms in Cancer [PDF]
Frontiers in Cell and Developmental Biology, 2021 Bruton’s tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies.
Xianhui Wang +3 more
doaj +3 more sources
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies [PDF]
Frontiers in Cell and Developmental Biology, 2021 Bruton’s tyrosine kinase (BTK) was discovered due to its importance in B cell development, and it has a critical role in signal transduction downstream of the B cell receptor (BCR).
Stefan F. H. Neys +2 more
doaj +5 more sources
Role of Bruton’s tyrosine kinase in B cells and malignancies [PDF]
Molecular Cancer, 2018 Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Simar Pal Singh +2 more
doaj +4 more sources
Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase [PDF]
Journal of Biological Chemistry, 2000 Bruton's tyrosine kinase (Btk), a nonreceptor cytoplasmic tyrosine kinase belonging to the Tec family of kinases, has been shown to be critical for B cell proliferation, differentiation, and signaling. Loss-of-function mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA), a primary immunodeficiency in humans, and the less severe ...
Abdalla J. Mohamed +5 more
openalex +5 more sources
Bruton's tyrosine kinase: oncotarget in myeloma [PDF]
Oncotarget, 2012 Our findings therefore provide a strong rationale for investigating Btk inhibitors in MM and WM to target both tumor cells and their supporting BM microenvironment and thereby both suppress tumor cell growth and abrogate MM-induced bone disease.
Yu-Tzu Tai, Kenneth C. Anderson
openalex +5 more sources
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors [PDF]
Frontiers in Immunology, 2021 C. I. Edvard Smith +3 more
doaj +3 more sources
Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma [PDF]
International Journal of Molecular Sciences, 2021 Multiple myeloma (MM), a clonal plasma cell disorder, disrupts the bones’ hematopoiesis and microenvironment homeostasis and ability to mediate an immune response against malignant clones. Despite prominent survival improvement with newer treatment modalities since the 2000s, MM is still considered a non-curable disease.
Tulin Budak-Alpdogan +11 more
openaire +4 more sources
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
Frontiers in Cell and Developmental Biology, 2021 Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description
Lauren E. Kueffer +2 more
doaj +1 more source
Second-generation inhibitors of Bruton tyrosine kinase [PDF]
Journal of Hematology & Oncology, 2016 Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported.
Jingjing Wu +3 more
openaire +3 more sources